SERA logo

Sera Prognostics (SERA) Company Overview

Profile

Full Name:

Sera Prognostics, Inc.

Sector:

Healthcare

Country:

United States

IPO:

July 15, 2021

Indexes:

Not included

Description:

Sera Prognostics is a healthcare company focused on improving pregnancy outcomes. They develop advanced tests to assess the risk of complications during pregnancy, helping healthcare providers make informed decisions. Their goal is to enhance maternal and fetal health through innovative diagnostic solutions.

Key Details

Price

$4.42

Annual Revenue

$306.00 K(+14.18% YoY)

Annual EPS

-$1.16(+18.88% YoY)

Annual ROE

-42.86%

Beta

0.81

Events Calendar

Earnings

Next earnings date:

Mar 20, 2025

Recent quarterly earnings:

Nov 6, 2024

Recent annual earnings:

Mar 20, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Aug 10, 23 Citigroup
Neutral
Nov 10, 22 Citigroup
Neutral
Sep 14, 22 Berenberg
Buy
Aug 29, 22 Oppenheimer
Outperform
Apr 27, 22 Berenberg
Buy
Mar 30, 22 Citigroup
Neutral
Nov 19, 21 Oppenheimer
Outperform
Aug 9, 21 William Blair
Outperform
Aug 9, 21 Cowen & Co.
Outperform
Aug 9, 21 Citigroup
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Sera Prognostics?
  • Does Sera Prognostics pay dividends?
  • What sector is Sera Prognostics in?
  • What industry is Sera Prognostics in?
  • What country is Sera Prognostics based in?
  • When did Sera Prognostics go public?
  • Is Sera Prognostics in the S&P 500?
  • Is Sera Prognostics in the NASDAQ 100?
  • Is Sera Prognostics in the Dow Jones?
  • When was Sera Prognostics's last earnings report?
  • When does Sera Prognostics report earnings?
  • Should I buy Sera Prognostics stock now?

What is the ticker symbol for Sera Prognostics?

The ticker symbol for Sera Prognostics is NASDAQ:SERA

Does Sera Prognostics pay dividends?

No, Sera Prognostics does not pay dividends

What sector is Sera Prognostics in?

Sera Prognostics is in the Healthcare sector

What industry is Sera Prognostics in?

Sera Prognostics is in the Medical Devices industry

What country is Sera Prognostics based in?

Sera Prognostics is headquartered in United States

When did Sera Prognostics go public?

Sera Prognostics's initial public offering (IPO) was on July 15, 2021

Is Sera Prognostics in the S&P 500?

No, Sera Prognostics is not included in the S&P 500 index

Is Sera Prognostics in the NASDAQ 100?

No, Sera Prognostics is not included in the NASDAQ 100 index

Is Sera Prognostics in the Dow Jones?

No, Sera Prognostics is not included in the Dow Jones index

When was Sera Prognostics's last earnings report?

Sera Prognostics's most recent earnings report was on Nov 6, 2024

When does Sera Prognostics report earnings?

The next expected earnings date for Sera Prognostics is Mar 20, 2025

Should I buy Sera Prognostics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions